
Roberto La Forgia
Founder & CEO
Graduated in Chemistry and Pharmaceutical Technologies (University of Bari). More than 17 years of international experience in the pharmaceutical and radiopharmaceutical sector. GMP expert and Authorized QP by AIFA. Founder of the Apulian company Beforpharma srl, an innovative company specialized in radiopharmaceutical services and development of integrated systems for the diagnosis and treatment of tumors. Co-inventor of the PSMA Cold Kit technology for the preparation of radiopharmaceuticals labeled with Ga68 - Lu177 - Ac225.

Maria De Bari
Chief Operating Officer
Responsible for B2B technical services; coordinates the team in charge of validation, production and quality control of radiopharmaceuticals; manages the research and development activities of BFP research projects. As Quality Assurance Manager, Maria verifies and approves all technical documentation, both Production and Quality Control, ensures the high quality standards of the services provided.

Onofrio Porcelli
Administrative Manager
As Administrative Manager he deals with the reporting of project activities and the bureaucratic-administrative management for partnerships of which BFP is leader. As Project Manager he is responsible for coordinating the partners involved, to link operations and deliverables for all ongoing projects.

Anna Pacelli
Head of Quality Control
Responsible for Quality Control of radiopharmaceuticals. On the B2B side he plans and carries out analyzes on raw materials and finished products, in compliance with the highest quality standards of the radiopharmaceutical legislation. It is responsible for drawing up all technical documents relating to quality controls in both the chemical-physical and microbiological fields and for approving, by means of appropriate analyzes, the radiopharmaceuticals before their administration to patients.

Lorenzo Castrigno
Quality Assurance Specialist
Supervisor of production processes and quality control, according to the GMP guidelines (EudraLex - Volume 4: Part I, “Basic Requirements for Medicinal Products”; Part III, “GMP related documents”), with particular attention to the Annex #1, Annex #13 and Annex #15.